Last reviewed · How we verify
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes: A Prospective, Randomized, Clinical Study - The AID-JUNCT Trial
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Details
| Lead sponsor | University of Bern |
|---|---|
| Phase | Phase 3 |
| Status | RECRUITING |
| Enrolment | 42 |
| Start date | 2025-02-14 |
| Completion | 2026-06 |
Conditions
- Type 1 Diabetes (T1D)
Interventions
- Tirzepatide
Primary outcomes
- Change TIR — At week 16 of treatment.
Mean difference in 24/7 CGM percentage time spent between 3.9 and 10 mmol/L (TIR) between groups.
Countries
Switzerland